Literature DB >> 35184258

Impact of Preventive Strategies on Gastrointestinal Complications in Elderly Patients on Concomitant Use of Oral Anticoagulants and Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Cohort Study.

Suhyun Lee1, Kyu-Nam Heo1, Mee Yeon Lee1, Woo-Youn Kim1, Young-Mi Ah2, Jaekyu Shin3, Ju-Yeun Lee4.   

Abstract

INTRODUCTION: Despite growing evidence showing an increased risk of concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants, few studies have investigated whether proton pump inhibitors can prevent gastrointestinal (GI) complications in patients receiving both NSAIDs and anticoagulants.
OBJECTIVE: We aimed to evaluate the risk of serious GI complications and the impact of GI preventive strategies on the concomitant use of NSAIDs and anticoagulants.
METHODS: Our nationwide cohort study using Korea's claims data included elderly patients (aged ≥ 65 years) who started anticoagulants and NSAIDs from 2016 to 2017. The outcome was serious GI complications defined as hospitalization or emergency department visits with GI bleeding or perforation. A Cox regression analysis was performed using time-dependent variables and propensity score matching.
RESULTS: In total, 92,379 patients were identified. Compared with non-prophylaxis, proton pump inhibitors and selective cyclooxygenase-2 inhibitors were associated with a 64% [adjusted hazard ratio, 0.36 (95% confidence interval 0.25-0.53)] and 74% [adjusted hazard ratio, 0.26 (95% confidence interval 0.19-0.36)] lower risk of serious GI complications, respectively. Cyclooxygenase-2 inhibitor use was not different from the use of non-selective NSAIDs with proton pump inhibitors for the prevention of serious GI complications. H2-receptor antagonists did not reduce the risk of serious GI complications compared with non-prophylaxis during concomitant non-selective NSAID and anticoagulant therapy.
CONCLUSIONS: Proton pump inhibitors or cyclooxygenase-2 inhibitors used as GI preventive strategies did not completely eliminate but lowered the risk of serious GI complications among elderly patients receiving both NSAIDs and anticoagulants.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35184258     DOI: 10.1007/s40264-022-01150-x

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  8 in total

Review 1.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study.

Authors:  Anton Pottegård; Anne Broe; Jesper Hallas; Ove B Schaffalitzky de Muckadell; Annmarie T Lassen; Anders B Lødrup
Journal:  Therap Adv Gastroenterol       Date:  2016-05-26       Impact factor: 4.409

3.  NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

Authors:  Dinç Dinçer; Ece Ulukal Karancı; Mete Akın; Haydar Adanır
Journal:  Turk J Gastroenterol       Date:  2019-06       Impact factor: 1.852

4.  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Authors:  Loren Laine; Sean P Curtis; Byron Cryer; Amarjot Kaur; Christopher P Cannon
Journal:  Lancet       Date:  2007-02-10       Impact factor: 79.321

5.  Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study.

Authors:  Arnar B Ingason; Jóhann P Hreinsson; Arnar S Ágústsson; Sigrún H Lund; Edward Rumba; Daníel A Pálsson; Indriði E Reynisson; Brynja R Guðmundsdóttir; Páll T Önundarson; Einar S Björnsson
Journal:  Ann Intern Med       Date:  2021-10-12       Impact factor: 25.391

6.  Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation.

Authors:  William P Glasheen; Tristan Cordier; Rajiv Gumpina; Gil Haugh; Jared Davis; Andrew Renda
Journal:  Am Health Drug Benefits       Date:  2019 Jun-Jul

7.  Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits.

Authors:  Alberto Lué; Angel Lanas
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

8.  Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015.

Authors:  Kamil E Barbour; Charles G Helmick; Michael Boring; Teresa J Brady
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-10       Impact factor: 17.586

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.